Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC
Shots:
- J&J reported P-III (MARIPOSA) trial data assessing Rybrevant + Lazcluze vs osimertinib or Lazcluze alone as a 1L treatment of locally advanced or metastatic NSCLC pts (n=1074) with EGFR ex19del or L858R substitution mutations
- At 37.8mos. mFU, trial showed superior OS, with mOS not reached vs 36.7mos. for osimertinib-treated pts, plus 56% vs 44% pts were alive at 3.5yrs. Projections suggest Rybrevant + Lazcluze could extend mOS by at least 12mos.; data to be shared with global health authorities & presented at ELCC 2025
- Trial also showed improvements in other 2EPs, incl. intracranial PFS, DoR, & ORR, with prolonged time to symptomatic progression (TTSP) by over 14mos. vs osimertinib (43.6 vs 29.3mos.)
Ref: J&J | Image: J&J
Related News:- Johnson & Johnson Reports the US FDA’s Approval of Subcutaneous & Intravenous Tremfya for Active Crohn’s Disease (CD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
